Fulcrum Therapeutics, Inc. based in Cambridge, Massachusetts, made headlines on November 07, 2025, for granting non-statutory stock options to two new employees. This clinical-stage biopharmaceutical company, listed on Nasdaq as FULC, focuses on developing small molecules to benefit patients with rare genetic diseases. The stock options were given as part of the 2022 Inducement Stock Incentive Plan, as amended, to encourage the new employees to join the company in compliance with Nasdaq Listing Rule 5635(c)(4).